Guanabenz Modulation of eIF2B Activity in Vanishing White Matter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Vanishing White Matter (VWM) are inadequate, with existing therapies failing to effectively slow disease progression and improve quality of life for patients, as they primarily target symptoms rather than addressing the underlying cellular stress and translation initiation defects caused by eIF2B mutations.
Innovation Solution
The use of Guanabenz, an α-2 adrenergic receptor agonist, which indirectly regulates eIF2B activity by modulating the phosphorylation status of eIF2, potentially alleviating cellular stress by prolonging eIF2 phosphorylation and adjusting protein synthesis rates, thereby offering a novel therapeutic approach for VWM.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat VWM, then symptom management is provided, but disease progression is not effectively slowed and underlying cellular stress defects are not addressed
Solution Approach 1:
The patent converts the harmful chronic activation of cell stress pathways (which causes cellular dysfunction and disease progression) into a beneficial effect by using guanabenz to modulate eIF2B activity. This regulation reduces pathological stress responses while maintaining essential protein synthesis, thereby slowing disease progression and improving treatment efficacy without requiring complete pathway inhibition
Solution Approach 2:
The patent changes the parameter of eIF2B activity regulation from its mutated, chronically stressed state to a modulated state through guanabenz treatment. By altering the phosphorylation status of eIF2 and consequently the activity of eIF2B, the treatment shifts the cellular state from pathological stress activation to a more balanced functional state, addressing both symptom management and underlying defects
2Productivity
If eIF2B activity is increased to improve protein synthesis, then translation initiation is enhanced, but cellular stress pathways become overactivated causing harm
Solution Approach 1:
The patent applies dynamic regulation of eIF2B activity through guanabenz treatment, allowing the system to adapt protein synthesis rates to cellular needs without fixed overactivation. This dynamic modulation enables enhanced translation initiation when beneficial while preventing pathological stress pathway activation, resolving the contradiction between productivity improvement and harmful stress activation
Solution Approach 2:
The patent utilizes feedback mechanisms where guanabenz treatment monitors and regulates eIF2B activity levels. By modulating the phosphorylation status of eIF2 in response to cellular conditions, the system provides feedback control that enhances protein synthesis when needed while preventing excessive activation of stress pathways, thus balancing productivity with cellular health
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Guanabenz treatment in VWM mouse models shows marked improvement in disease markers, slowing disease progression, reducing episodes of rapid deterioration, and prolonging life expectancy, suggesting its potential to increase walking ability and quality of life for patients.
Implementation Method 1
Guanabenz, an agonist for the α-2 adrenergic receptor, has been used to treat arterial hypertension for 30 years without major side effects. Recent discoveries indicate that Guanabenz has α-2 adrenergic receptor independent functions and can also regulate eIF2B activity indirectly through regulating the phosphorylation status of eIF2
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3C
AI summary
The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the sub ject. The sample is typically a post mortem sample.